JWCTF (JW (Cayman) Therapeutics Co) 5-Year EBITDA Growth Rate: 33.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

JWCTF JW (Cayman) Therapeutics Co Ltd JWCTF
26 GF Score
Price $0.20
GF Value $0.37
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is JW (Cayman) Therapeutics Co 5-Year EBITDA Growth Rate?

JW (Cayman) Therapeutics Co JWCTF -4.38% 26 5-Year EBITDA Growth Rate is 33.00% as of Dec. 2025. GuruFocus rates JWCTF with a GF Score™ of 26/100 and a GF Value™ of $0.37 (Possible Value Trap). The stock has 3 warning signs investors should review.

JW (Cayman) Therapeutics Co's EBITDA per Share for the six months ended in Dec. 2025 was $-0.10.

During the past 3 years, the average EBITDA Per Share Growth Rate was 15.90% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 33.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of JW (Cayman) Therapeutics Co was 50.90% per year. The lowest was -35.70% per year. And the median was 14.20% per year.

JW (Cayman) Therapeutics Co  (OTCPK:JWCTF) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

JW (Cayman) Therapeutics Co 5-Year EBITDA Growth Rate Related Terms

JWCTF vs VRTX, REGN, RVMD: 5-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, JW (Cayman) Therapeutics Co's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

JW (Cayman) Therapeutics Co 5-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, JW (Cayman) Therapeutics Co's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where JW (Cayman) Therapeutics Co's 5-Year EBITDA Growth Rate falls into.


JWCTF
26GF Score
JW (Cayman) Therapeutics Co Ltd JWCTF
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

JW (Cayman) Therapeutics Co 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 33.00% mean?
JW (Cayman) Therapeutics Co (JWCTF) has a 5-Year EBITDA Growth Rate of 33.00% as of Dec. 2025. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for JW (Cayman) Therapeutics Co and its competitors.
Is JW (Cayman) Therapeutics Co's 5-Year EBITDA Growth Rate too high?
JW (Cayman) Therapeutics Co's current 5-Year EBITDA Growth Rate is 33.00%. Overall, JW (Cayman) Therapeutics Co has a GF Score™ of 26/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does JW (Cayman) Therapeutics Co's 5-Year EBITDA Growth Rate compare to VRTX and REGN?
JW (Cayman) Therapeutics Co's 5-Year EBITDA Growth Rate of 33.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Biotechnology company?
A good 5-Year EBITDA Growth Rate depends on the Biotechnology industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for JW (Cayman) Therapeutics Co and its competitors. JW (Cayman) Therapeutics Co's current 5-Year EBITDA Growth Rate is 33.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JW (Cayman) Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, JW (Cayman) Therapeutics Co (JWCTF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.37, compared to a current price of $0.20 — trading 45.3% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 33.00%. JW (Cayman) Therapeutics Co's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For JW (Cayman) Therapeutics Co (JWCTF), the current 5-Year EBITDA Growth Rate is 33.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is JW (Cayman) Therapeutics Co (JWCTF) Overvalued in 2026?

Based on GuruFocus' analysis, JW (Cayman) Therapeutics Co stock appears to be undervalued. The current stock price of $0.20 is trading 45.3% below its estimated GF Value™ of $0.37. GuruFocus considers JW (Cayman) Therapeutics Co to be Possible Value Trap.

Key valuation signals for JWCTF:

  • 5-Year EBITDA Growth Rate: 33.00%
  • GF Value™: $0.37 vs. price of $0.20 (45.3% below fair value)
  • GF Score™: 26/100 with 3 warning signs

No single metric tells the full story. See the JWCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

JW (Cayman) Therapeutics Co Business Description

Other Exchanges 02126:Hong KongJNY:Germany
Address No. 699 Zhong Ke Road, 5th Floor, Building B, Wison Center, Pudong New District, Shanghai, CHN
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
26GF Score

Get the complete analysis for JWCTF

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.20
Price
$0.37
GF Value